SAM
MRNA icon

Summit Asset Management’s Moderna MRNA Stock Holding History

Summit Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,070
Closed -$252K – 155
2023
Q2 		$252K Hold
2,070
– – 0.07% 134
2023
Q1 		$318K Hold
2,070
– – 0.09% 113
2022
Q4 		$372K Hold
2,070
– – 0.11% 103
2022
Q3 		$245K Hold
2,070
– – 0.08% 128
2022
Q2 		$296K Buy
2,070
+2
+0.1% +$286 0.09% 119
2022
Q1 		$356K Buy
2,068
+205
+11% +$34.5K 0.1% 112
2021
Q4 		$473K Sell
1,863
-868
-32% -$254K 0.13% 94
2021
Q3 		$1.05M Buy
2,731
+940
+52% +$347K 0.33% 41
2021
Q2 		$421K Buy
1,791
+220
+14% +$39.3K 0.13% 92
2021
Q1 		$206K Buy
+1,571
New +$228K 0.07% 142
2020
Q4 		– Sell
-3,174
Closed -$225K – 137
2020
Q3 		$225K Buy
+3,174
New +$221K 0.09% 118

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Summit Asset Management's MRNA Position: Q3 2023 in Review

Summit Asset Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 2,070 shares — an estimated $252K sold.

Summit Asset Management first reported a position in MRNA in Q3 2020 and held it in 11 quarters. The position peaked at $1.05M in Q3 2021. 888 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Summit Asset Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Summit Asset Management sold 2,070 Moderna shares in Q3 2023, an estimated $252K.
  • Summit Asset Management first reported a position in Moderna in Q3 2020 and held it in 11 quarters.
  • Summit Asset Management's Moderna position peaked at $1.05M in Q3 2021.
  • 888 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Summit Asset Management's 13F filing for Q3 2023, filed 6 Nov 2023.